Ascendis: Why I'm Skeptical On Takeover Rumors, Long-Term Targets [Seeking Alpha]
Ascendis Pharma A/S - American Depositary Shares (ASND)
Last ascendis pharma a/s - american depositary shares earnings: 11/18 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ascendispharma.com
Company Research
Source: Seeking Alpha
Despite robust growth and pipeline catalysts, ASND trades at a 15x P/S multiple and remains unprofitable, prompting a Hold rating. Key near-term catalyst is the FDA PDUFA decision for TransCon CNP in February; failure could trigger a sharp sell-off. Vision 2030 targets €5bn revenue, but achieving sustained 40% CAGR appears ambitious; takeover rumors add speculative upside. Looking for a portfolio of ideas like this one? Members of Haggerston BioHealth get exclusive access to our subscriber-only portfolios. Learn More » Richard Drury/DigitalVision via Getty Images Investment Overview The stock of Ascendis Pharma ( ASND ) has risen in value by 1,000% over the past decade, climbing from a price of ~$20 to $235 per share at the time of writing. Stock is also up 85% on a 1-year This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of NVO either through stock ownership, options, or other derivatives. I wrote this article myself
Show less
Read more
Impact Snapshot
Event Time:
ASND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ASND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ASND alerts
High impacting Ascendis Pharma A/S - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
ASND
News
- Ascendis Pharma A/S (NASDAQ:ASND) had its price target raised by analysts at Bank of America Corporation from $246.00 to $260.00. They now have a "buy" rating on the stock.MarketBeat
- RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets [Yahoo! Finance]Yahoo! Finance
- Ascendis Pharma A/S (NASDAQ:ASND) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.MarketBeat
- Ascendis Pharma A/S (NASDAQ:ASND) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.MarketBeat
- Ascendis: Why I'm Sceptical On Takeover Rumours, Long-Term Targets [Seeking Alpha]Seeking Alpha
ASND
Earnings
- 11/12/25 - Miss
ASND
Sec Filings
- 1/14/26 - Form 6-K
- 1/13/26 - Form 144
- 1/12/26 - Form 6-K
- ASND's page on the SEC website